News

McKnight's Long-Term Care News1d

FDA OKs subcutaneous lecanemab injection for maintenance dosing for early Alzheimer’s

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of ...

FDA approves subcutaneous Leqembi for treatment of early Alzheimer's disease

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance ...
Medscape2d

FDA OKs Subcutaneous Lecanemab Maintenance Dosing for Early AD

After 18 months of intravenous administration of lecanemab (Leqembi), patients may now transition to subcutaneous delivery using the Leqembi Iqlik autoinjector.
Healio2d

FDA approves Leqembi at-home subcutaneous injection in early Alzheimer’s

The FDA has approved a supplemental biologics application for Leqembi Iqlik subcutaneous injection for maintenance dosing in ...
pharmaphorum2d

Eisai moves swiftly to expand subcutaneous Leqembi label

The once-weekly subcutaneous autoinjector picked up an FDA approval late last week that clears the way for it to be an ...
BioSpace3d

Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi

While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction ...
KPVI2d

FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) ...